Frédéric Sweeney, PhD joined bioMérieux in February of 2016 as Vice President of Business Development and Strategic Alliances. Dr. Sweeney’s role at bioMérieux is to work closely with bioMérieux’ business units and affiliates companies to lead new technology search and evaluation, and to establish strategic partnerships including R&D collaborations, licensing, co-development, investments and M&As. Prior to bioMérieux, Fred was Head of Business Development at T2 Biosystems (NASDAQ:TTOO), a Boston-based, early stage commercial company developing innovative diagnostic solutions. Fred’s responsibility at T2 Bio was to establish strategic partnerships and collaborations with key external stakeholders leveraging the power of T2MR, T2 Bio’s platform technology.
Fred has also been part of the founding team of Tornado Spectral Systems, a Toronto-based company developing and manufacturing high-performance optical spectroscopy instrumentation. He started his career as part of the investment team of VenGrowth Private Equity Partners, a large Venture Capital and Private Equity firm which was also based in Toronto.
A graduate of the Biochemistry Department of McGill University, he then obtained his PhD in Molecular and Medical Genetics from the University of Toronto where he was a Terry Fox Awardee of the National Institute of Cancer of Canada.